Supporting your biologics development process
We have a wide range of experience in the analytics of biomolecules and are able to offer tailor made services as well as method qualification and transfer.
You want to learn more how we can support your drug development?
Biomolecules expertise
BIOSIMILAR REVIEW
VelaLabs’ expertise covers a variety of biomolecules including biosimilars. The Biosimilar Review shows a market overview and can be downloaded free of charge below.
FACT SHEETS
These fact sheets will show you VelaLab’s analytical portfolio in the area of biomolecules.
You will also get information about the mode of action, patent status, market, originator and research status of these selected biosimilars, antibodies, mabs and hormones:
- Abatacept
- Adalimumab
- Aflibercept
- Alemtuzumab
- Bevacizumab
- Cetuximab
- Darbepoetin alfa
- Denosumab
- Eculizumab
- Epoetin alfa
- Etanercept
- FSH
- G‑CSF
- Golimumab
- HGH
- Infliximab
- Insulin
- Interferon-beta-1a
- Ipilimumab
- Natalizumab
- Nivolumab
- Omalizumab
- PegG-CSF
- Pembrolizumab
- Pertuzumab
- PTH
- Ramucirumab
- Ranibizumab
- Rituximab
- Tocilizumab
- Trastuzumab
- Ustekinumab
COMPETITIVE REPORT:
As we know the market, we have a competitive field available for all of these biomolecules:
the competitive fields are researched with state-of-the-art methods and are routinely updated.
These analysis are available upon request – see an example for a competitive field for adalimumab in our Biosimilar Review